Platform Strategies for Synthetic Oligonucleotide Drug Substances
Organic Process Research & Development · 15.12.2023 · 27 (12) · 2211-2222
DOI: 10.1021/acs.oprd.3c00303 ↗Kurz gefasst
Fachartikel in der Zeitschrift Organic Process Research & Development, online erschienen am 30.11.2023. Verfasst von Dominik Altevogt und 8 weiteren Autor:innen. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
High Resolution Image Download MS PowerPoint Slide Synthetic therapeutic oligonucleotide drug substances are commonly manufactured using the same basic unit operations, i.e., solid phase oligonucleotide synthesis, cleavage and deprotection, purification, and isolation. The platform nature of oligonucleotide drug substance manufacturing provides opportunities to optimize process development, streamline process validation, and expedite regulatory submissions. In this publication, we discuss a modular approach to platform strategies for synthetic oligonucleotide drug substances, the opportunities associated with the application of platform knowledge, and how such information could be presented in regulatory filings.
Zitieren
APA
Altevogt, D., Cedillo, I., Curtis, C., Diorazio, L. J., Faber, J., Jones, M. T., Telford, A., Turner, G., & Wetter, C. (2023). Platform Strategies for Synthetic Oligonucleotide Drug Substances. Organic Process Research & Development, 27(12), 2211-2222. https://doi.org/10.1021/acs.oprd.3c00303
Vancouver
Altevogt D, Cedillo I, Curtis C, Diorazio LJ, Faber J, Jones MT, et al. Platform Strategies for Synthetic Oligonucleotide Drug Substances. Organic Process Research & Development. 2023;27(12):2211-2222. doi:10.1021/acs.oprd.3c00303
BibTeX
@article{Altevogt2023,
author = {Altevogt, Dominik and Cedillo, Isaiah and Curtis, Corrine and Diorazio, Louis J. and Faber, Jesse and Jones, Michael T. and Telford, Alex and Turner, Gillian and Wetter, Christian},
title = {Platform Strategies for Synthetic Oligonucleotide Drug Substances},
journal = {Organic Process Research & Development},
year = {2023},
volume = {27},
number = {12},
pages = {2211--2222},
doi = {10.1021/acs.oprd.3c00303}
}
EUVIMED